Skip to content

Human Trial Effect Evaluation of Xinluosu Tablets in Helping to Maintain Normal Platelet Aggregation Function and Beneficial to Blood Flow Health Function

Human Trial Effect Evaluation of Xinluosu Tablets in Helping to Maintain Normal Platelet Aggregation Function and Beneficial to Blood Flow Health Function

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300068286
Enrollment
Unknown
Registered
2023-02-14
Start date
2022-09-20
Completion date
Unknown
Last updated
2023-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

human platelet aggregation function, blood flow health function

Interventions

Control group:placebo

Sponsors

The 983rd Hospital of the Chinese People's Liberation Army Joint Logistic Support Force
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. People aged 35-65, regardless of gender; 2. No history of allergies, no immune diseases, no obvious diseases of blood vessels or blood systems, and no abnormalities in laboratory tests (routine hematuria, liver and kidney function, blood sugar and blood lipid, coagulation function, etc.); 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Obvious vascular or hematological diseases, hypertension or infection; 2. Anyone who takes immune preparations, hormone drugs, aspirin, drugs containing aspirin, and other drugs that can change the function of platelets or the coagulation system; 3. Low platelet count (whole blood < 100 x 10^9/mL); 4. The hematocrit is lower (male < 40%, female < 37%); 5. Prothrombin time (PT) is outside of the normal reference range; 6. Abnormal hemoglobin (male < 120 g/L, female < 110 g/L); 7. Abnormal menstrual cycle, taking contraceptives or hormone replacement therapy; 8. Pregnancy; 9. Take fish oil and evening primrose oil supplement orally for one month; 10. Not suitable for venous blood collection personnel; 11. Subjects must not donate more than 560ml of blood in the month prior to entering the study; 12. allergic to tomatoes and their components; 13. Patients with gastric ulcer; 14. Surgery or trauma occurred during the test; 15. Those who took items related to the test subject's function in a short period of time affected the judgment on the result; 16. Those who did not meet the inclusion criteria, did not take the test sample as required, or the observation results were affected by the incomplete information.

Design outcomes

Primary

MeasureTime frame
Platelet aggregation rate;

Secondary

MeasureTime frame
Coagulation function;Four items of blood lipid;blood sugar;

Countries

China

Contacts

Public ContactQi Wang

The 983rd Hospital of the Chinese People's Liberation Army Joint Logistic Support Force

kangao@kaotg.com+86 1703299000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026